EFFECT OF PIDOTIMOD ON PRODUCTION OF PRO- AND ANTI-INFLAMMATORY CYTOKINES EX VIVO

S.S. Grigoryan; A.M. Ivanova

EFFECT OF PIDOTIMOD ON PRODUCTION OF PRO- AND ANTI-INFLAMMATORY CYTOKINES EX VIVO

S.S. Grigoryan, A.M. Ivanova

Abstract

Pidotimod is per oral immunomodulator; its efficacy is conditioned by activation of different components of immune system. The efficacy of pidotimod was studied in frequently sick children; its influence on the production of pro- and anti-inflammatory cytokines with leucocytes in peripheral blood was evaluated. The study was performed ex vivo with 15 samples of peripheral blood of frequently sick children 4 years old. The rate of interferon (IFN) status, sensitivity to pidotimod, concentration of pro-inflammatory (IFN , Interleukin [Il] 18) and anti-inflammatory (Il 4, 10) cytokines were detected before and after processing the samples with the drug. Pidotimodex vivo induced more than 4 times increase of initially low production of IFN with leucocytes of peripheral blood (from 11.5 ± 3.4 to 51.8 ± 8.3 U/ml). It did not influence the production of IFN _ (432 ± 49 and 448 ± 30 U/ml — before and after processing the samples correspondingly). The drug stimulated production of IFN ex vivo; the concentration of IFN compared to its spontaneous production increased from 2.3 ± 0.9 to 11.8 ± 1.6 picogram/ml correspondingly. Stimulation of PGA-induced production of IFN was less expressed; it increased in correlation with the time of exposition 1.5–2.5 times higher compared to induction of IFN synthesis without the drug. The drug favored to increase of Il 18 level (spontaneous — from 23.5 ± 3.5 to 49.1 ± 2.2 pg/ml, induced — from 34.2 ± 2.4 to 47.8 ± 4.4 pg/ml) and Il 10 (from 6.7 ± 1.3 to 15.5 ± 0.9 pg/ml and from 20.6 ± 1.2 to 42.7 ± 2.5 pg/ml correspondingly). As the production of cytokines increased because of pidotimod, the level of Il 4 (as spontaneous, as induced one) decreased from 2.6 ± 0.8 to 0.5 ± 0.2 pg/ml correspondingly. Thus, pidotimod ex vivo stimulates the synthesis of IFN , Il 10 and 18 and decreases the level of Il 4. These effects favor to the activation of Th1 immune response of organism.
Key words: frequently sick children, cytokines, pidotimod.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2011; 10 (4): 129–132)

About the Authors

S.S. Grigoryan

N.F. Gamaleya Scientific Center of Epidemiology and Microbiology, Moscow

A.M. Ivanova

N.F. Gamaleya Scientific Center of Epidemiology and Microbiology, Moscow

References

1. Coppi G., Falcone A., Manzardo S. Protective effects of pidotimod against experimental bacterial infections in mice. Arzneim. Forsch. Drug. Res. 1994; 44: 1417–1421.

2. Dianzani C., Colangelo D., Tonso E. et al. In vivo antiviral effects of pidotimod. Arzneim. Forsch. Drug. Res. 1994; 44: 1431–1433.

3. Caramia G., Clemente E., Solli R. et al. Efficacy and safety of pidotimod in the treatment of recurrent recpiratory infections in children. Arzneim. Forsch. Drug. Res. 1994; 44: 1480–1484.

4. Carreddu P., Venturosi V., Corsini A. Pidotimod in the treatment of recurrent respiratory infections in pediatric patients. Arzneim. Forsch. Drug. Res. 1994; 44: 1485–1489.

5. Aivasis V., Hatzimichail A., Papachristou A. et al. Clinical evaluation and changes of the respiratory epithelium function after administration of pidotimod in children with recurrent respiratory tract infections. Minerva. Pediatr. 2002; 54: 345–349.

6. Харламова Ф.С., Учайкин В.Ф., Кладова О.В., Бевза С.Л. Применение препарата пидотимод при острой респираторной инфекции у часто болеющих детей. Вопросы современной педиатрии. 2009; 8 (2): 21–27.

7. Намазова-Баранова Л.С., Харит С.М., Тузанкина И.А. и др. Результаты многоцентрового исследования применения препарата пидотимод для профилактики острых респираторных инфекций у часто болеющих детей. Вопросы современной педиатрии. 2010; 9 (2): 40–44.

8. Сорока Н.Д. Повторные респираторные заболевания в детском возрасте: иммунотерапия с помощью препарата пидотимод (Имунорикс). Consilium Medicum (Педиатрия). 2010; 3: 88–92.

9. Benetti G.P., Fugazza L., Stamba B.M. et al. Ex vivo evaluation of pidotimod activity on cell-mediated immunity. Arzneim. Forsch. Drug. Res. 2004; 44: 1476–1479.

10. Aw D., Silva A.B., Palmer D.B. Immunose nescence emerging challenger for an aging population. Immunology. 2007; 120: 435–446.

11. Giagulli C., Noerber M., Avolio M. еt al. Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level. Inter. Immunopharm. 2009; 9: 1366–1373.

12. Григорян С.С., Майоров И.А., Иванова А.М., Ершов Ф.И. Оценка интерферонового статуса людей по пробам цельной крови. Вопросы вирусологии. 1988; 4: 433–436.

13. Григорян С.С., Арутюнян Р.А. Способ определения индивидуальной чувствительности лейкоцитов крови людей к лекарственному препарату. Патент РФ 2009 г. № 2324705.

14. Schoenborn J.R., Wilson C.B. Regulation of interferon gamma during innate and adaptive immune responses. Adv. Immunol. 2007; 96: 41–101.

15. Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin 18 is unique cytokine that stimulates both Th1 and Th2 responses. Cytokine Growth Factors Rev. 2001; 12 (1): 53–72.

16. Meiler F., Zumkehr J., Klunger S. et al. In vivo switch to IL 10 secreting T–regulatory cells in high dose allergen. J. Exp. Med. 2008; 205: 2887–2898.

Review

For citations:

Grigoryan S., Ivanova A. EFFECT OF PIDOTIMOD ON PRODUCTION OF PRO- AND ANTI-INFLAMMATORY CYTOKINES EX VIVO. Current Pediatrics. 2011;10(4):129–132.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International.

ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Current Pediatrics

EFFECT OF PIDOTIMOD ON PRODUCTION OF PRO- AND ANTI-INFLAMMATORY CYTOKINES EX VIVO

Abstract

About the Authors

References

Review

For citations:

Cookies policy